BioCentury
ARTICLE | Clinical News

ImuLyme: Discontinued Development

February 22, 2000 8:00 AM UTC

Aventis Pasteur Inc., Swiftwater, Penn. Product: ImuLyme Business: Infectious diseases Therapeutic category: Immune stimulation, Bacterial infection Target: Immune cells Description: Recombinant outer...